Physician profile
Mark T Murphy
NPI 1740294818
$21,825.27
in general payments reported to CMS, 2019-2025
19 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $164 · 2021: $479 · 2022: $622 · 2023: $2,991 · 2024: $282 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $5,254 · Food and Beverage: $1,457 · Consulting Fee: $1,013 · Education: $58.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,119.00 |
| Travel and Lodging | $5,254.21 |
| Food and Beverage | $1,456.89 |
| Consulting Fee | $1,012.50 |
| Education | $58.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19,960.56 | 2019-2025 | Sublocade |
| Abbvie INC. | $366.78 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $326.02 | 2020-2022 | |
| Braeburn INC. | $193.22 | 2024-2025 | Brixadi |
| Orexo US, INC. | $185.10 | 2019-2022 | |
| Alkermes, INC. | $175.63 | 2019-2022 | |
| Biomarin Pharmaceutical INC. | $128.75 | 2019 | |
| Amgen INC. | $78.13 | 2019 | |
| Lilly USA, LLC | $69.91 | 2019 | |
| Daiichi Sankyo INC. | $68.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.97 | 2019 | |
| Pfizer INC. | $45.44 | 2019 | |
| Biodelivery Sciences International, INC. | $40.65 | 2019 | |
| Mdd US Operations, LLC | $35.73 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $23.43 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.53 | 2019 | |
| Allergan, INC. | $14.22 | 2019 | |
| Merck Sharp & Dohme LLC | $13.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.